Perjeta 420 mg concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion
2020-004696-41
Phase 2 small_molecule active
Quick answer
Perjeta 420 mg concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion for Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ breast cancer is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ breast cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active